Xeris Biopharma Holdings Expands Workforce with 181,500 Inducement Equity Grants to New Employees

Xeris Biopharma Expands Workforce with Inducement Equity Grants

Xeris Biopharma Holdings, Inc., a Chicago-based biopharmaceutical company, takes a significant step in enhancing its workforce by granting restricted stock units (RSUs) to 19 new employees. Announced on January 2, 2025, the company allocates a total of 181,500 shares under its Inducement Equity Plan. This initiative aims to attract talented individuals who are not currently part of Xeris or its subsidiaries, adhering to NASDAQ Listing Rules. The RSUs will vest over a period of three years in equal annual installments, contingent on the new hires' continued service with the company. This strategic move not only bolsters the company’s human capital but also underscores Xeris’ commitment to fostering a robust work environment that promotes innovation and excellence in patient care.

By recruiting new talent, Xeris Biopharma positions itself to enhance its capabilities in developing and commercializing a diverse range of therapies. The company currently markets three significant products: Recorlev®, which treats endogenous Cushing’s syndrome; Gvoke®, a ready-to-use glucagon for severe hypoglycemia; and Keveyis®, a medication for primary periodic paralysis. These offerings reflect Xeris’ focus on addressing critical healthcare needs through innovative solutions. With a growing portfolio, the company aims to leverage its newly expanded workforce to drive further advancements in its therapeutic offerings and deliver improved outcomes for patients.

In addition to its established products, Xeris is actively pursuing new developments within its pipeline. A notable candidate is XP-8121, a Phase 3-ready once-weekly subcutaneous injection of levothyroxine intended for hypothyroidism treatment. Furthermore, Xeris is exploring various early-stage programs powered by its proprietary technology platforms, XeriSol® and XeriJect®. This commitment to research and development highlights the company's growth-oriented strategy in the biopharmaceutical sector, emphasizing its focus on innovation and patient-centric solutions.

As Xeris Biopharma continues to expand its workforce and enhance its product offerings, the company remains dedicated to improving patient outcomes through cutting-edge therapies. For more information about Xeris and its initiatives, the public can visit their website or connect with the company on social media platforms such as X, LinkedIn, and Instagram.